Biogen News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

05.12.24	Eisai And Biogen : Mexico Approves LEQEMBI For Early Alzheimer's Disease Treatment (RTTNews)
19.11.24	UCB And Biogen: Dapirolizumab Pegol Meets Primary Endpoint In Phase 3 PHOENYCS GO Study (RTTNews)
19.11.24	Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity (GlobeNewswire)
18.11.24	Samsung Bioepis, Biogen Get European Commission Approval For Opuviz, A Biosimilar To Aflibercept (RTTNews)
15.11.24	Eisai Gets Positive Opinion From CHMP In European Union For Lecanemab In Early Alzheimer's Disease (RTTNews)
14.11.24	Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease (GlobeNewswire)
31.10.24	Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference (GlobeNewswire)
30.10.24	Biogen Q3 Results Top Estimates; Boosts FY24 Adj. EPS Outlook (RTTNews)
30.10.24	Biogen And Neomorph Collaborate To Develop Molecular Glue Degraders For Alzheimer's And More (RTTNews)
29.10.24	Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases (GlobeNewswire)
29.10.24	Biogen Names Daniel Quirk Chief Medical Officer And Head Of Medical Affairs - Quick Facts (RTTNews)
29.10.24	Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer (GlobeNewswire)
28.10.24	Biogen Appoints Robin Kramer As CFO To Replace Michael MCDonnell (RTTNews)
28.10.24	Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025 (GlobeNewswire)
27.10.24	Biogen's Phase 2 Study Shows Promising Results For Felzartamab In IgA Nephropathy (RTTNews)
27.10.24	Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024 (GlobeNewswire)
24.10.24	Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference (GlobeNewswire)
22.10.24	Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024 (GlobeNewswire)
09.10.24	Biogen: Felzartamab Receives Breakthrough Therapy Designation - Quick Facts (RTTNews)
09.10.24	Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients (GlobeNewswire)
08.10.24	New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA (GlobeNewswire)
26.09.24	Sage To Resume Full Ownership Of SAGE-324 Program As Biogen Terminates Collaboration Deal (RTTNews)
24.09.24	Biogen: Phase 3 PHOENYCS GO Study With Dapirolizumab Pegol Meets Primary Endpoint (RTTNews)
24.09.24	UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024 (GlobeNewswire)
20.09.24	Samsung Bioepis, Biogen Announce Positive CHMP Recommendation For OPUVIZ In Europe (RTTNews)
12.09.24	Biogen Board Appoints Two New Independent Directors (GlobeNewswire)
04.09.24	Biogen Reports Positive Topline Data From DEVOTE Study Of Higher Dose Regimen Of Nusinersen In SMA (RTTNews)
04.09.24	Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA (GlobeNewswire)
22.08.24	Eisai And Biogen : Leqembi Approved In Great Britain For Early Alzheimer's Disease (RTTNews)
04.08.24	Weekly Biotech Buzz: FGEN Cuts Jobs, FDA OKs ADAP's Groundbreaking Cell Therapy, ME Rebuffs CEO Bid (RTTNews)
01.08.24	Biogen Q2 Results Top Estimates; Boosts FY24 Outlook (RTTNews)
30.07.24	New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alz (GlobeNewswire)
30.07.24	Biogen, Beckman Coulter, Fujirebio To Develop Tau Pathology Blood Test For Alzheimer's Disease (RTTNews)
30.07.24	Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease (GlobeNewswire)
26.07.24	Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union (GlobeNewswire)
24.07.24	Sage Therapeutics, Biogen Say Phase 2 KINETIC 2 Study Of SAGE-324 In Essential Tremor Fails (RTTNews)
02.07.24	Biogen Completes Acquisition of Human Immunology Biosciences (GlobeNewswire)
28.06.24	“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China (GlobeNewswire)
24.06.24	Biogen Says European Commission Grants TOFIDENCE Biosimilar Approval For Multiple Indications (RTTNews)
24.06.24	TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union (GlobeNewswire)
10.06.24	Eisai : FDA Accepts SBLA On LEQEMBI For Early Alzheimer's Treatment (RTTNews)
10.06.24	FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease (GlobeNewswire)
31.05.24	Biogen : EU Approves Qalsody To Treat Rare, Genetic Form Of Amyotrophic Lateral Sclerosis (RTTNews)
30.05.24	Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS (GlobeNewswire)
22.05.24	Biogen To Buy Human Immunology Biosciences In Deal Valued At Up To $1.8 Bln (RTTNews)
22.05.24	Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences (GlobeNewswire)
16.05.24	Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis (GlobeNewswire)
15.05.24	Eisai Initiates Rolling BLA To FDA For LEQEMBI For Early Alzheimer's Disease Treatment (RTTNews)
15.05.24	Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track St (GlobeNewswire)
26.04.24	Biogen's Tofidence Gets Positive CHMP Opinion For Rheumatoid Arthritis,Juvenile Arthritis & COVID-19 (RTTNews)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

24.12.24		Börse New York: Dow Jones zeigt sich zum Handelsende fester
24.12.24		Zuversicht in New York: Dow Jones am Dienstagnachmittag mit Gewinnen
24.12.24		Dow Jones-Handel aktuell: Dow Jones steigt am Dienstagmittag
24.12.24		Börse New York: NASDAQ 100-Anleger greifen am Dienstagmittag zu
24.12.24		Freundlicher Handel: Letztendlich Gewinne im Euro STOXX 50
24.12.24		Dienstagshandel in New York: NASDAQ 100 startet in der Gewinnzone
24.12.24		NYSE-Handel: Dow Jones beginnt Dienstagshandel mit Gewinnen